Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2025 06:00 ET | Source: R3 Vascular

R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE® Drug Eluting Bioresorbable Scaffold

MOUNTAIN VIEW, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...
January 13, 2025 06:00 ET | Source: R3 Vascular

R3 Vascular Secures WCG IRB Approval and CMS Category B Medicare Coverage for the ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease

MOUNTAIN VIEW, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...
July 09, 2024 14:25 ET | Source: R3 Vascular

R3 Vascular Appoints Josh Smale as its Vice President of Global Clinical and Scientific Affairs

R3 Vascular Inc. is pleased to announce the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs.
May 09, 2024 12:00 ET | Source: R3 Vascular

R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO

R3 Vascular, Inc. announced the closing of its $87 million Series B financing round and the appointment of a new President and Chief Executive Officer
March 01, 2024 06:43 ET | Source: Research and Markets

Peripheral Arterial Disease (PAD) Therapeutics Global Strategic Research Report 2024

Dublin, March 01, 2024 (GLOBE NEWSWIRE) -- The "Peripheral Arterial Disease (PAD) Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global...
June 20, 2023 16:07 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)

PAD, characterized by vascular inflammation and associated calcification, affects 8.5 million people in the United States and contributes to more than 50,000 limb amputations annually, yet there are...
September 20, 2022 10:00 ET | Source: Persistence Market Research

Peripheral Vascular Devices Market estimated to surge ahead at a CAGR of 6.6% by the end of 2032 – Persistence Market Research

New York, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The global peripheral vascular devices market was worth US$ 4.5 Bn in 2021 and t is expected to expand at a high CAGR of 6.6% over the forecast period...
August 30, 2022 06:23 ET | Source: Exactitude Consultancy

Hyperlipidemia Drugs Market Size, Share, Qualitative Analysis and Industry Growth Factors and is growing at a CAGR of 2.2% by 2029

Luton, Bedfordshire, United Kingdom, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed...
November 19, 2015 06:11 ET | Source: Holy Name Medical Center

Holy Name Medical Center First in the Northeast to Offer Magellan(TM) Robotic System

TEANECK, N.J., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Physicians at Holy Name Medical Center are the first in the Northeast to use the Magellan™ Robotic System, which enables them to perform complex,...